Notably, targeting VEGFA in diseases characterized by abnormal vascularization (for example, retinal disorders and tumors) often results in suboptimal efficacy, leading to rebound angiogenesis or damage to normal vasculature59. Here, VEGFA is linked to retinal disorder.